Details of the SBP | SYNBIP

General Information of Synthetic Binding Protein (SBP) (ID: SBP002007)
SBP Name	BiTE AMG-211
Synonyms	MT111; MEDI-565
Molecular Weight	55 kDa
Design Method	Traditional methods (Site-directed mutagenesis and/or Directed evolution)
Highest Status	Phase I; Discontinued

Protein Scaffold Information of This SBP
Scaffold ID	PS018 Scaffold Info					[1] , [2]
Scaffold Name	BiTE
Scaffold Class	Antibody fragment
Fold Type	Beta-Sheets + Loops

Binding Target(s) of This SBP (BTS)

BTS Name	Details	Mechanism	Application	Affinity	Research Organization	Ref
T-cell surface glycoprotein CD3	BTS Info	Stimulator	GI adenocarcinoma [ICD-11: 2D40]	N.A.	Amgen; MedImmune	[1] , [2]
Carcinoembryonic antigen	BTS Info	Stimulator	GI adenocarcinoma [ICD-11: 2D40]	N.A.	Amgen; MedImmune	[1] , [2]

Clinical Trial Information of This SBP
NCT01284231	Click to show the Detail
Indication	Gastrointestinal Adenocarcinomas
Phase	Phase I
Title	A Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas
Status	Completed
Sponsor	MedImmune LLC
NCT02291614	Click to show the Detail
Indication	Relapsed or Refractory Gastrointestinal Adenocarcinoma
Phase	Phase I
Title	A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 211 Administered as Continuous Intravenous Infusion in Subjects With Relapsed/Refractory Gastrointestinal Adenocarcinoma
Status	Terminated?(Immunogenicity and Business Decision)
Sponsor	Amgen
NCT02760199	Click to show the Detail
Indication	Advanced Gastrointestinal Cancer
Phase	Phase I
Title	89Zr-AMG211 PET Imaging Study
Status	Completed
Sponsor	University Medical Center Groningen

References

1	Single-Chain Variable Fragment-Based Bispecific Antibodies: Hitting Two Targets with One Sophisticated Arrow. Mol Ther Oncolytics. 2019 Mar 23;14:38-56.
2	Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89 Zr-AMG211 Targeting CEA-Positive Tumors. Clin Cancer Res. 2018 Oct 15;24(20):4988-4996.